Is CRISPR Therapeutics Stock Too Risky to Buy Right Now? [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
Its gene-editing therapies can be game changers for patients living with illnesses and conditions that might otherwise be difficult to treat. The company already has a promising approved therapy in Casgevy, which regulators first approved in 2023 to treat patients with sickle cell disease. It has also obtained approval as a treatment for transfusion-dependent beta thalassemia. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » But the issue with CRISPR is that it's been a slow rollout, and its business continues to incur significant losses. Is it still too risky a stock to buy right now? Should you consider holding off on buying CRISPR Therapeutics? Image source: Getty Images. CRISPR may not be profitable for a while One of the biggest problems with Casgevy is that its list price is a staggering $2.2 millio
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought [Yahoo! Finance]Yahoo! Finance
- Here's What Analysts Are Saying About CRISPR Therapeutics AG (CRSP) [Yahoo! Finance]Yahoo! Finance
- Assessing CRISPR Therapeutics (CRSP) Valuation After FDA Draft Guidance And Recent Weak Earnings [Yahoo! Finance]Yahoo! Finance
- FDA Draft Guidance Puts CRISPR Therapeutics Rare Disease Outlook In Focus [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics touts zugo-cel CAR-T gains, eyes autoimmune expansion at Citi oncology summit [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 2/12/26 - Miss
CRSP
Sec Filings
- 2/20/26 - Form 4
- 2/20/26 - Form 4
- 2/17/26 - Form SCHEDULE
- CRSP's page on the SEC website